Drug intelligence / Profile preview

ADB-106

Development stage: Preclinical
Lead developer: Adolore Biotherapeutics
Modality: Gene Therapies

Overview

ADB-106 is a gene therapy product developed by Adolore Biotherapeutics for the treatment of chronic eye pain. It is part of Adolore's pipeline leveraging innovative gene therapy vectors expressing CA8* analgesic peptides (ADLR-1001). The therapy is based on recombinant disabled herpes simplex virus vectors (rdHSV-CA8*) that transduce sensory neurons to provide pain relief. ADB-106 is currently available for partnering opportunities.

Targets

KCNQ (Potassium voltage-gated channel subfamily Q (Kv7))

Beyond the preview

Go deeper on ADB-106.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADB-106.

Explore the full profile